The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
BPC-157 + KPV — structural repair meets anti-inflammatory signaling
KPV has primarily in vitro and mouse IBD model data. BPC-157 has extensive animal gut data. No human trial exists for either compound in GI indications, nor for the combination.
The gut indication is arguably BPC-157's strongest mechanistic case — it was isolated from gastric juice and has extensive GI animal data. KPV's anti-inflammatory mechanism is well-characterized in vitro. But neither has cleared a human clinical trial, and IBD is a complex immune disease where "gut healing" compounds have repeatedly failed in translation. This is a D-grade stack used by people who feel they have exhausted other options.
What each compound contributes — and why it's in the stack.
Structural gut repair — mucosal healing, intestinal permeability reduction, NSAID/alcohol damage protection
Full BPC-157 chapterAnti-inflammatory signaling — alpha-MSH derived tripeptide, NF-κB inhibition, gut mucosa protection
Full KPV chapterBPC-157 and KPV address different layers of gut pathology. BPC-157 primarily drives structural repair — mucosal healing, tight junction restoration, and vascular repair in damaged gut tissue. KPV (Lys-Pro-Val), derived from the C-terminal of alpha-MSH, inhibits NF-κB and directly suppresses inflammatory mediators at the intestinal epithelium. The combination is theoretically sound: repair the structure (BPC) while dampening the inflammatory signaling (KPV) that drives ongoing damage.
This reflects how this combination is used in practice. It is not a prescribing guide and does not constitute medical advice.
| Phase | Timing | Compounds & doses | Notes |
|---|---|---|---|
| Oral protocol (gut-targeted) | Daily | BPC-157 500 mcg oral + KPV 500 mcg–1 mg oral, both on empty stomach | Oral route prioritized for gut indications. BPC-157 is acid-stable. KPV gut absorption not fully characterized but appears active in rodent models via oral route. |
| Timing | 30–60 min before food | — | Empty stomach maximizes mucosal contact time before food disrupts the luminal environment. |
| Cycle | 6–12 weeks, then reassess | — | Gut healing timelines are longer than soft-tissue injury. Most protocols run 8–12 weeks before evaluating response. |
Adults with diagnosed or suspected intestinal permeability, IBD (Crohn's, UC) seeking adjunctive options beyond standard care, SIBO recovery, or NSAID-induced gut damage. Should be used alongside, not instead of, gastroenterologist-supervised treatment for diagnosed IBD.
Informational only. Ranges vary significantly by vendor, vial size, and country. No pharmaceutical-grade source exists for most of these compounds; figures are not a buying guide.